IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

HOPEWELL PHARMA VENTURES, INC.,
Petitioner

v.

MERCK SERONO S.A.,
Patent Owner

_____

Case IPR2023-00480
U.S. Patent No. 7,713,947

_____

**PETITIONER HOPEWELL PHARMA VENTURES, INC.'S MOTION FOR
PRO HAC VICE ADMISSION OF JOHN CHRISTOPHER ROZENDAAL
UNDER 37 C.F.R. § 42.10(c)**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

PETITIONER'S UPDATED EXHIBIT LIST

| Exhibit #	Description
1001	De Luca, G., et al., "Cladribine Regimen for Treating Multiple Sclerosis," U.S. Patent No. 7,713,947 B2 (filed June 18, 2007; issued May 11, 2010)
1002	Declaration of Aaron Miller, M.D.
1003	*Curriculum Vitae* for Aaron Miller, M.D.
1004	File History for U.S. Patent No. 7,713,947
1005	*Intentionally Left Blank*
1006	Noseworthy, J.H., et al., "Multiple Sclerosis," *The New England Journal of Medicine*, 343(13):938-952 (2000)
1007	Neuhaus, O., et al., "Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection," *TRENDS in Pharmaceutical Sciences*, 24(3):131-138 (2003)
1008	Weiner, H.L., et al., "Immunotherapy of Multiple Sclerosis," *Annals of Neurology*, 23(3):211-222 (1988)
1009	Wingerchuk, D.M., et al., "Biology of Disease, Multiple Sclerosis: Current Pathophysiological Concepts," *Laboratory Investigation*, 81(3):263-281 (2001)
1010	Kurtzke, J.F., "Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)," *Neurology*, 33:1444-1452 (1983)
1011	*Intentionally Left Blank*
1012	Whitaker, J.N., "Rationale for Immunotherapy in Multiple Sclerosis," *Annals of Neurology*, 36:S103-S107 (1994)
1013	Stelmasiak, Z., et al., "A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting-relapsing multiple sclerosis," *Medical Science Monitor*, 4(1):4-8 (1998)
1014	Beutler, E., et al., "The treatment of chronic progressive multiple sclerosis with cladribine," *Proceedings of the National Academy of Sciences*, USA 93:1716-1720 (1996)
1015	Tortorella, C., et al., "Cladribine Ortho Biotech Inc," *Current Opinion in Investigational Drugs*, 2(12):1751-1756 (2001)
1016	Langtry, H.D., et al., "Cladribine, A Review of its Use in Multiple Sclerosis," *BioDrugs*, 9(5):419-433 (1998)

Exhibit #	Description
1017	Rudick, R.A., et al., "Management of Multiple Sclerosis," *The New England Journal of Medicine*, 337(22):1604-1611 (1997)
1018	Rice, G.P.A., et al., "Cladribine and progressive MS, Clinical and MRI outcomes of a multicenter controlled trial," *Neurology*, 54:1145-1155 (2000)
1019	Barkhof, R., et al., "Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis," *Neuroradiology*, 36:382-387 (1994)
1020	Pirko, I. and Rodriguez, M., "Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial," *Archives of Neurology*, 61:1148-1149 (2004)
1021	Weiner, H.L., et al., "Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group," *Neurology*, 43:910-918 (1993)
1022	Bodor, N. and Dandiker, Y., "Oral Formulations of Cladribine," International Publication No. WO 2004/087101 A2 (filed March 26, 2004; published October 14, 2004)
1023	Grieb, P., et al., "Effect of Repeated Treatments with Cladribine (2-Chlorodeoxyadenosine) on Blood Counts in Multiple Sclerosis Patients," *Archivum Immunologiae Experimentalis*, 43:323-327 (1995)
1024	Schultz, T.W., et al., "Cyclodextrine Cladribine Formulations," U.S. Patent No. 6,194,395 B1 (filed February 25, 1999; issued February 27, 2001)
1025	File History for U.S. Patent No. 8,377,903
1026	Beutler, E., "Use of Substituted Adenine Derivatives for Treating Multiple Sclerosis," U.S. Patent No. 5,506,214 B2 (filed February 18, 1993; issued April 9, 1996)
1027	Docket Report, *Merck KGaA et al. v. Hopewell Pharma Ventures, Inc.*, Case No. 1:22-cv-01365-GBW (D.Del.)
1028	Docket Report, *Merck KGaA et al. v. Accord Healthcare, Inc.*, Case No. 1:22-cv-00974-GBW (D.Del.)
1029	United States District Courts - National Judicial Caseload Profile, June 2022
1030	*Curriculum Vitae* for Nancy E. Adams, Ed.D.

Exhibit #	Description
1031	Romine, J. S., et al., "A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis," *Proceedings of the Association of American Physicians*, 111(1):35-44 (1999)
1032	Docket Report, *Merck KGaA et al. v. Aurobindo Pharma USA, Inc., et al.*, Case No. 1:23-cv-00039-GBW (D.Del.)
1033	Bloom, P.M., "Treatment of Multiple Sclerosis with Lymphocytapheresis and Chemo-Immunosuppression," U.S. Patent No. 4,964,848 (filed June 27, 1988; issued October 23, 1990)
1034	*Intentionally Left Blank*
1035	*Intentionally Left Blank*
1036	Lassmann, H., et al., "Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy," *TRENDS in Molecular Medicine*, 7(3):115-121 (March 2001)
1037	Lublin, F. D., et al., "Defining the clinical course of multiple sclerosis: Results of an international survey," *Neurology*, 46:907-911 (1996)
1038	Casanova, B., et al., "High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study," *Multiple Sclerosis*, 8:59-63 (2002)
1039	Publisher's Record for Stelmasiak (EX1013)
1040	Declaration of Nancy E. Adams, Ed.D.
1041	*Intentionally Left Blank*
1042	Shurkovich, S., et al., "Randomized study of antibodies to INF-γ and TNF-α in secondary progressive multiple sclerosis," *Multiple Sclerosis*, 7:277-84 (2001)
1043	Khoury, S. J., "Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies?," *Archives of Internal Medicine*, 158:565-73 (1998)
1044	Roitt, I. M., "Essential Immunology, Sixth Edition," Blackwell Scientific Publications, 1-29 (1988) (Excerpt)
1045	Filippi, M., et al., "The effect of cladribine on T1 'black hole' changes in progressive MS," *Journal of Neurological Sciences*, 176:42-44 (2000)
1046	Romine, J. S., et al., "Cladribine: Use in Therapy of Multiple Sclerosis," *Biodrugs*, 7(5):386-93 (1997)

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.